第48回日本神経学会総会
＜シンポジウム7-1＞認知症「治療を展望したAlzheimer病の早期診断―MCIから初期Alzheimer病へ」
オーバービュー
井原 康夫
同志社大学生命医科学部設置準備室〔〒619-0225 京都府木津川市木津川台4-1-1 同志社大学 学研都市キャンパス 快風館〕
It is now one hundred years since the first publication on Alzheimer's disease by Alois Alzheimer. Since 1980's deciphering Alzheimer's disease has greatly quickened, and investigators currently think that it becomes possible to treat or prevent Alzheimer's disease that is the major socioeconomical concern in all the developed countries. We owe this current understanding to three major advances, development of Aβ vaccination and γ-modifiers, and a series of large-scale prospective studies.
J-ADNI is being undertaken from this fall, which follows the protocols by US-ADNI. The major goal is establishment of the surrogate marker for AD based on MRI data. In addition, this project would provide more clarification of MCI and dementia themselves and their differentiation.
In view of the temporal profile of Alzheimer disease, it is essential to detect at-risk people who carry senile plaques (amyloid) but are cognitively normal. Even in MCI more than 50% of neurons in layer 2 is already lost. For such very early detection of at-risk people biomaker would be helpful. According to sink hypothesis, there is chemical equilibrium of Aβ between in plasma, CSF and senile plaques. Thus what we should do is to find insoluble Aβ-specific fragments or modifications in the peripheral blood.
(臨床神経, 47：902−904, 2007)
key words：Alzheimer病, 早期診断, 治療
（受付日：2007年5月16日）
